Flexible Cancer Target Capture Panels for Genomic Profiling
Cancer research and diagnostics are evolving rapidly in the precision medicine era. While traditional approaches focused on single-gene testing for specific cancer types, today’s standard is shifting toward molecular and genomic profiling based on each patient’s unique genetic landscape. NGS-based multi-gene panels have become essential tools in both research and clinical settings. In particular, the ability to reliably detect variants from challenging sample types such as FFPE tissues or cfDNA and to identify low-frequency mutations (low VAF) from limited DNA input has become a critical factor in panel selection. In addition, demand is growing for comprehensive biomarker analysis beyond SNVs and indels, including CNVs, fusions, MSI, and TMB, all within a single workflow.
In response to these trends, Celemics offers not a single product, but a complete portfolio of Cancer Target Capture Panel line-ups, enabling researchers to choose the optimal solution for their specific study objectives.
Cancer Panel Portfolio Designed Around Research Objectives
The Celemics Cancer Panel portfolio is a structured Target Capture Panel solution designed to support a wide range of cancer research scenarios, including hereditary cancer, somatic cancer, and liquid biopsy applications.
Key Features of Celemics Cancer Panels
- Robust performance in difficult genomic regions: Stable target capture even in AT/GC-rich and masking regions
- Broad sample compatibility: Supports Blood, Tissue, FFPE, and Plasma cfDNA
Reliable detection even with low-input or degraded samples - Expanded variant interpretation scope: Beyond SNVs and indels, panels can cover CNVs, fusions, MSI, and TMB depending on research goals
- Platform flexibility: Compatible with Illumina, Thermo Fisher, and MGI, as well as long-read platforms such as PacBio and Oxford Nanopore
- Scalability and advanced analysis support: Gene add-on services for customization and expansion
CAS integration for advanced biomarker analysis including CNV, fusion, MSI, and TMB
1. A Dedicated Solution for Hereditary Cancer Research: OncoRisk Panel
The OncoRisk Panel is a 31-gene targeted panel designed for hereditary cancer research and testing, supporting genetic risk assessment and precision oncology studies. It includes not only SNVs and indels, but also CNV detection, ensuring comprehensive interpretation for hereditary cancer workflows. The panel supports multiple sample types including gDNA, blood, and FFPE, making it suitable for real-world clinical and research applications.
2. Expanding Somatic Cancer Research with the CancerScreen Line-up
The CancerScreen Core / 50 / 100 / 400 series provides scalable panel sizes depending on study objectives and research phases. Researchers can select the appropriate target size within the same product family, supporting stepwise workflows from initial screening to validation and expanded profiling.
- CancerScreen Core: 13 essential genes for early screening and key variant discovery
- CancerScreen 50: 54 major somatic cancer genes for intermediate coverage
- CancerScreen 100: 99 genes for extended research applications
- CancerScreen 400: 407 genes for high-density comprehensive profiling
3. Integrated DNA+RNA Profiling: CancerScreen Comprehensive
The CancerScreen Comprehensive Panel is designed for broad genomic profiling through combined DNA and RNA analysis.
- DNA: 697 genes + RNA: 68 genes
- Supports SNV, indel, CNV, fusion, MSI, and TMB
- Compatible with blood and tissue samples (FFPE and frozen)
4. A Comprehensive Panel Covering Immuno-Oncology Biomarkers: CancerMaster Panel
The CancerMaster Panel is an advanced somatic profiling solution designed to capture not only genomic alterations but also key immuno-oncology biomarkers.
It supports all major variant types including SNVs, indels, CNVs, and rearrangements along with predictive biomarkers such as TMB and MSI.
CancerMaster further expands coverage by including viral genomes associated with cancer, such as:
- Epstein–Barr Virus (EBV)
- • Human Papillomaviruses (HPV)
Panel Highlights
- Coverage: 524 genes (full CDS) plus tumor-immune customized regions
- Targets: SNV, indel, CNV, rearrangement, TMB, MSI, EBV, HPV
5. Liquid Biopsy Solution Optimized for Low Input Samples: Liquid Biopsy Panel
The Celemics Liquid Biopsy Panel is a ready-to-use target capture panel designed for ctDNA-based liquid biopsy research, optimized for low-input and low-VAF mutation detection. This line-up consists of three cancer-type–specific panels validated with clinical plasma samples:
- Colorectal Cancer Panel
– 15 genes (full CDS)
– Includes APC, KRAS, TP53 - Breast Cancer Panel
– 27 genes (full CDS)
– Includes BRCA1/2, ESR1, PIK3CA - Lung Cancer Panel
– 28 genes
– 8 full CDS + 20 hotspot exonic regions
– Includes EGFR, KRAS, ALK
All panels support plasma cfDNA input ≥20 ng and provide stable SNV/indel detection. Proprietary probe design ensures high capture efficiency for fragmented ctDNA, while UMI technology reduces PCR duplication and sequencing noise—enabling accurate detection of rare variants even at very low allele frequencies.
Additional Specialized Cancer Research Panels
Beyond CancerScreen and Liquid Biopsy products, Celemics also provides specialized panels optimized for specific cancer research purposes.
- CancerScreen Focus Panel
– Includes key somatic genes + TERT promoter
– Detects SNV, indel, CNV, rearrangement
– Optimized for companion diagnostics and therapy-linked variant research - CancerScreen CUP Panel
– Targeted methylation sequencing panel for Cancer of Unknown Primary (CUP)
– Supports tumor-origin classification based on DNA methylation patterns - BRCA 1/2 Panel
– Full CDS coverage plus UTR, promoter, and splicing sites
– Detects SNV/indel as well as large rearrangements and CNVs
– Ideal for high-resolution breast and ovarian cancer gene research
Celemics provides a structured Cancer Target Capture portfolio designed to support diverse oncology research workflows—from hereditary risk assessment and somatic mutation profiling to ctDNA-based liquid biopsy analysis. Each panel is developed with consideration for challenging sample types, low-input conditions, and expanded biomarker coverage, enabling consistent and reproducible genomic profiling across different research settings. By aligning panel design with specific study objectives, researchers can achieve reliable data generation while maintaining workflow efficiency and analytical flexibility.
Explore the full Celemics Cancer Target Capture portfolio and discover the right panel for your research objectives.
👉 https://www.celemics.com/products/ready-to-use-ngs-panel/somatic-cancer/
#CancerGenomics
#PrecisionOncology
#TargetCapture
#NGSPanel
#SomaticMutation
#HereditaryCancer
#LiquidBiopsy
#ctDNA
#GenomicProfiling
#Celemics